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Abstract Neuroblastoma is the most common extracra-
nial solid tumor of infancy. Amplification of MYCN
oncogene is found in approximately 20 % of all neuro-
blastoma patients and correlates with advanced disease
stages, rapid tumor progression, and poor prognosis,
making this gene an obvious therapeutic target. However,
being a transcriptional factor MYCN is difficult for phar-
macological targeting, and there are currently no clinical
trials aiming MYCN protein directly. Here we describe an
alternative approach to address deregulated MYCN
expression. In particular, we focus on the role of a 30
untranslated region (30UTR) of the MYCN gene in the
modulation of its mRNA fate and identification of com-
pounds able to affect it. The luciferase reporter construct
with the full length MYCN 30UTR was generated and
subsequently integrated in the CHP134 neuroblastoma cell
line. After validation, the assay was used to screen a 2000
compound library. Molecules affecting luciferase activity
were checked for reproducibility and counter-screened for
promoter effects and cytotoxic activity resulting in selec-
tion of four hits. We propose this cell-based reporter gene
assay as a valuable tool to screen chemical libraries for
compounds modulating post-transcriptional control mech-
anisms. Identification of such compounds could potentially
result in development of clinically relevant therapeutics for
various diseases including neuroblastoma.
Keywords Post-transcriptional control  Screening 
Luciferase  30UTR  MYCN  Neuroblastoma
Introduction
Post-transcriptional regulation is a rapid and dynamic cel-
lular process allowing for fast changes in protein levels in a
transcription-independent way. Post-transcriptional control
processes comprise various mechanisms such as mRNA
processing (polyadenylation, capping, splicing), mRNA
export and localization, mRNA turnover, and translation
efficiency. These processes are known to be mediated by
RNA-binding proteins (RBPs) and non-coding RNAs that
bind to specific sequences or secondary structures, typically
within mRNA 50UTRs and 30UTRs [1]. In general, the
degree of ‘‘uncoupling’’ between transcriptome (total
mRNA quantity) and translatome (quantity of mRNA loaded
on polysomes) abundance is very high [2], indicating that the
variations induced by post-transcriptional control mecha-
nisms are significant for final shaping of the phenotype.
If a therapeutically relevant protein is derived from an
mRNA with a predominant post-transcriptional regulation,
specific targeting of these mechanisms can yield important
implications [3]. For example, the human oncogene MDM2
has been recently shown to bind to AU-rich elements
(AREs) in the mRNA 30UTR of yet another oncogene,
MYCN, stabilizing it [4]. Accordingly, two small-molecule
antagonists of MDM2, Nutlin-3, and MI-63, might be of
particular interest in treating MYCN-dependent diseases,
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such as high-risk neuroblastoma [5]. Indeed, Nutlin is
currently enrolled as potential therapeutics in preclinical
phase of testing.
While understanding of post-transcriptional regulation
mechanisms has increased, this knowledge has not been
accompanied by similar progresses in identifying com-
pounds capable of modulating mRNA fate through inter-
ference with these mechanisms. Reporter cell-based assays
offer a versatile and technically simple way to test mole-
cules in high-throughput format [6]. However, until
recently this kind of assay has been mainly focused on the
identification of promoter-targeting compounds [7]. A
similar approach in which a reporter gene is flanked by the
50UTR and/or 30UTR of a gene of interest could become a
valuable tool for identification of molecules targeting post-
transcriptional control mechanisms [8–10].
Neuroblastoma (NB) is a tumor derived from primitive
cells of the sympathetic nervous system and is the most
common extracranial solid tumor in childhood. The hall-
mark of NB is heterogeneity of clinical behavior, which
ranges from spontaneous regression to rapid progression
and death despite multimodal intensive therapy [11]. Being
a relatively rare disease, NB disproportionally accounts for
approximately 15 % of children cancer related deaths [12].
Therefore, new therapies are urgently needed.
Clinical and biological features, such as age at diagnosis,
disease stage, numerical (ploidy) and structural chromo-
somal alterations (MYCN gene amplification; 1p, 3p, 11q
deletions; 17q gain), are used to estimate patient’s prognosis
[13]. MYCN amplification in NB patients is an independent
prognostic factor present in about 20 % of all cases. It is
strongly related to advanced disease stages, rapid tumor
progression and adverse outcome, making this gene an
obvious therapeutic target. Being a transcriptional factor,
however, it is difficult for pharmacological targeting, and
there are currently no clinical trials targeting MYCN protein
directly, highlighting the need of alternative approaches.
A detailed computational study of the 30UTR of the
MYCN mRNA demonstrated that it is almost entirely highly
conserved in vertebrate phylogenesis. As depicted in Fig. 1,
there is an experimental evidence for at least two RBPs (HuD
and MDM2) to modulate MYCN mRNA fate through
binding to its 30UTR [4, 14, 15]. It also contains at least eight
experimentally validated miRNA binding sites [16–19]. All
of this would predict for a highly regulated 30UTR, therefore
making it possible to modulate MYCN protein levels
through interferences exerted at its 30UTR level.
Hence, we focused our efforts on (1) development of a
biological model that allows us to investigate the role of
MYCN 30UTR in modulating post-transcriptional regula-
tory processes, and (2) identification of compounds that




The NB cell lines CHP134, IMR-32, KELLY, LA-N-1,
LA-N-2, NB69, SK-N-AS, SK-N-DZ, SK-N-BE(2), and
SK-N-SH were obtained from the European Collection of
Cell Cultures (ECACC); CHP-126, MHH-NB-11 and SiMa
were purchased from Deutsche Sammlung von Mikroor-
ganismen und Zellkulturen GmbH (DSMZ); CHP-212 and
SK-N-MC from American Type Culture Collection
(ATCC). The cell lines STA-NB-1, -7 and -10 were kindly
provided by Dr. Peter F. Ambros from Children’s Cancer
Research Institute, Vienna, Austria. All cell lines were
cultured in humidified 37 C, 5 % CO2 incubator in a
media prepared following the instructions of the suppliers.
Real-Time Quantitative PCR
MYCN copy number status was determined using real-time
quantitative PCR (qPCR) approach described elsewhere
[20]. Briefly, gDNA was isolated following the protocol of
DNeasy Blood & Tissue Kit (Qiagen). qPCR was per-
formed on an Rotor-Gene 6000 real-time system (Corbett
Life Science). Each run included a standard curve of four
serial tenfold dilution points, normal human DNA (Roche)
with a disomic copy number of all genes, gDNA samples
from 18 NB cell lines and a no-template control. Ampli-
fication mixture (10 ll) for MYCN, BCMA and SDC4
contained 5 ng gDNA, 19 Kapa SYBR Fast qPCR Uni-
versal Master Mix (29) (Kapa Biosystems) and 300 nM of
corresponding primers (Eurofins MWG Operon) listed in
Table S1. The cycling conditions comprised 2 min at
95 C, 40 cycles at 95 C for 3 s, 60 C for 30 s and at
72 C for 1 s, followed by melting curve analysis. The
Fig. 1 Schematic diagram of the MYCN gene. The MYCN transcript
(NM_005378.4) is drawn to scale. Boxes represent the exons with
shaded regions corresponding to the CDS, lines represent introns. The
lower panel displays the zoomed-in view of MYCN 30UTR with
experimentally validated AREs (thick lines) and miRNA target sites
(zigzag lines). The individual RNA-binding proteins and miRNAs
with the corresponding reference sources in square brackets are
indicated
632 Mol Biotechnol (2014) 56:631–643
123
copy numbers of MYCN, BCMA and SDC4 genes in each
sample were interpolated from the raw Cq values using the
constructed standard curves and then calibrated against a
normal human DNA sample. MYCN copy number was
calculated by dividing the calibrated values by the geo-
metric mean copy number of BCMA and SDC4 reference
genes.
Total RNA was purified using RNeasy mini kit (Qiagen)
according to the provided protocol. For each sample,
cDNA was produced from 1 lg RNA following the pro-
tocol from iScript cDNA synthesis kit (BioRad). PCR
reactions were performed in a 10 ll reaction volume con-
taining 5 ng template cDNA, 19 Kapa SYBR Fast qPCR
Universal Master Mix (29) and 300 nM of forward and
reverse primers (Table S1). All reactions were carried out
on a Rotor-Gene 6000 real-time system with the cycling
conditions described above. qPCR amplification efficiency
was calculated for each gene using a relative standard
curve derived from a cDNA mixture of NB samples (a
tenfold dilution series with four measuring points). The
relative mRNA expression level of each gene was deter-
mined in Excel as described elsewhere [21]. The geometric
mean of four reference genes (HPRT1, SDHA, UBC, and
GAPDH) was used for normalization of MYCN expression
levels.
Western Blotting
To analyze MYCN protein level in 18 NB cell lines, total
proteins were extracted from pelleted cells in RIPA buffer
followed by three freezing/thawing cycles. CHP134 cells
treated with CPX for various time periods were harvested
and divided in two parts for subsequent total and cytosolic
protein isolation using RIPA and Buffer A (10 mM
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT,
0.05 % NP40), respectively. Following quantification with
Bradford reagent (Sigma), 10 lg total proteins or 20 lg of
cytoplasmic fraction were loaded and electrophoresed
using sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to nitrocellulose
membranes (BioRad). After blocking, membranes were
incubated with anti-MYCN (1:500, OP13, Calbiochem) or
anti-GAPDH (1:2000, sc-32233, SantaCruz) as primary
antibodies and goat anti-mouse IgG-HRP (SantaCruz) as
secondary antibodies. Blots were imaged with ChemiDoc
XRS? imaging system (BioRad) after addition of ECL
Select (for MYCN) or Prime (GAPDH) detection reagent
(Amersham).
Reporter Constructs
Reporter constructs containing the Firefly luciferase
reporter gene luc2 under control of a CMV viral promoter
and followed by either the whole MYCN 30UTR (pGL4.26-
MYCN) or the SV40 poly(A) region (pGL4.26-CTRL) as a
control were generated (Fig. S1). pGL4.74 encoding Re-
nilla luciferase was purchased from Promega. HuD over-
expressing plasmid was kindly provided by Daniele Peroni
(CIBIO, Trento, Italy).
Transient and Stable Transfections
Transient transfection experiments with DNA plasmids
were performed in CHP134, KELLY, SK-N-BE(2), and
SiMa neuroblastoma cell lines. The cells were seeded in
white 96-well plates (Nunc) at 10000, 15000, 20000, and
30000 cells per well, respectively, in 100 ll of complete
medium. After overnight incubation at 37 C and 5 % CO2,
cells were transfected by addition of the mixture containing
TurboFectin 8.0 (0.12–0.3 ll) and plasmid DNA
(0.04–0.1 lg) in 3:1 ratio in 10 ll of OPTI-MEM (Gibco).
Plasmid DNA represented a 5:1 mixture of either pGL4.26-
MYCN or pGL4.26-CTRL plasmids with pGL4.74
encoding Renilla luciferase. Luciferase activity was mea-
sured by Dual-Glo Luciferase Assay (Promega) according
to the protocol of the supplier using a Tecan Infinite M200
plate luminometer. The resulting values of the Firefly
luciferase activity were normalized to Renilla luciferase
activity in the same well. Each different condition was
assayed in 3–5 technical replicates and 3 independent
biological experiments.
To generate stable clones, CHP134 cells were plated on
a 12-well plate and the next day transfected with the
mixture containing 100 ll of OPTI-MEM, 2 lg of either
pGL4.26-MYCN or -CTRL plasmids and 6 ll of Turbo-
Fection 8.0 transfection reagent (OriGene). 24 h post-
transfection the cells were trypsinized and transferred to
10 cm dishes. Two days later, the selection of stable clones
was started by addition to the growing media of hygro-
mycin B (Life Technologies) at the final concentration of
110 lg/ml. After the stably transfected cells became visible
and could be picked, the cells were transferred to a 48-well
plate and expanded. All obtained clones were designated as
CHP134-MYCN or CHP134-CTRL followed by the num-
ber corresponding to a specific clone. Finally, the clones
were verified for luciferase activity level using One-Glo
luciferase assay (Promega) and for the integrity of CMV
promoter and MYCN 30UTR or SV40 late polyA regions
using PCR.
miR-34 mimic (Qiagen) and HuD overexpressing plas-
mid were transfected into CHP134-MYCN#3 cells using
modified reverse transfection protocol. 15000 cells were
plated in a white 96-well plate (Nunc) in 100 ll growth
medium. In about 30 min transfection complexes contain-
ing in 20 ll OPTI-MEM either 0.5 ll Lipofectamine
RNAiMAX reagent (Life Technologies) and 25 nM
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miR-34 or 0.45 ll TurboFectin 8.0 and 0.15 lg HuD
plasmid were added to the wells with loosely adhered cells.
miScript Inhibitor Negative Control (Qiagen) and pEGFP-
N1 plasmid (Clontech) were used for mock transfections.
Luciferase activity was assayed using One-Glo reagent in
48–72 h.
Primary Screening and Counter-Screening
The screening represented a cell-based assay of reporter
gene type. It was carried out in triplicates in the CHP134-
MYCN#3 stable clone with the Spectrum Collection small
molecule library (MicroSource Discovery). The library
screened consisted of 2000 compounds arranged in 8 rows
and 10 columns in 25 96-well plates at the concentration of
10 mM in DMSO. The screening was divided in three runs
with the batch size of 27 plates screened in one run. The
batch of 27 plates included library plates n.1-n.8?n.25
(first run), n.9-n.16?n.25 (second run) and n.16-
n.24?n.25 (third run), each plate screened in triplicate.
Thus, the library plate n.25 was assayed within all three
runs making possible inter-run comparison.
In each run CHP134-MYCN#3 cells were plated in 27
white 96-well plates (CulturePlate-96, PerkinElmer) at the
concentration of 15000 cells per well in 75 ll culture
medium using the Tecan EVO 200 robot. Next day the
cells were treated for 24 h at the final compound concen-
tration of 2 lM in each well (0.02 % DMSO). Columns 1
and 12 of each plate were used for vehicle-treated controls.
Luminescence signal was measured in 30 min after addi-
tion of One-Glo luciferase reagent on a Tecan F200 mul-
tiplate reader integrated with the robot. Experimental data
were pre-processed using normalization of all samples to
on-plate vehicle-treated controls. Hits were selected using
x  2SD as a hit selection threshold, where the mean value
x and SD are computed over all assay values [22]. The
generated hit list was further manually filtered as described
in the ‘‘Results’’ section.
The counter-screening was performed for the selected
112 hits, cherry-picked from stock library plates and dis-
tributed over two 96-well plates. The assay was carried out
in triplicates in CHP134-MYCN#3 and -CTRL#19 cells
plated in white (luciferase activity detection) and trans-
parent (viability assay) 96-well plates (PerkinElmer). The
cells were grown and treated following the protocol
described above. The raw luminescence signals of the
samples were normalized to on-plate vehicle-treated con-
trols. In addition to luminescent readout, cell viability was
assessed using the WST-1 assay (Roche) according to the
protocol of the supplier. Briefly, the WST-1 reagent was
added in an amount equal to 10 % of the culture volume
and the plates were returned to the incubator. Four hours
later the absorbance was measured at 450 nm on the Tecan
F200 multiplate reader. The percentage of viable cells
was calculated using the following equations: (Ti - Tz)/
(C - Tz) 9 100 if Ti C Tz and (Ti - Tz)/Tz 9 100 if
Ti \ Tz, where Tz (time zero) is an absorbance measure-
ment at the time of drug addition (performed in separate
control plates), control growth (C), and test growth (Ti) are
absorbance measurements in the presence of a vehicle and
a compound of interest, respectively.
Results
The MYCN 30UTR Ectopically Affects mRNA Stability
in NB Cells
MYCN amplification found in about 20 % of primary NBs
is associated with rapid tumor progression and poor prog-
nosis [13]. In order to set up a cell-based assay addressing
the question if deregulated MYCN expression could be
modulated through its 30UTR, the proper cellular model
had to be selected. With this in mind, we characterized 18
parental NB cell lines (cell lines directly derived from the
original tumor and not by in vitro cell subcloning) in terms
of MYCN levels. First, MYCN gene amplification was
tested using qPCR. As shown in Fig. 2a, 14 out of 18 tested
cell lines could be classified as MYCN-amplified (MNA),
though demonstrating heterogeneous levels of gene
amplification. Further, we validated whether MYCN
amplification indeed resulted in overexpression of its
mRNA and finally in comparable production of the protein.
In fact, all MNA cell lines demonstrated high MYCN
mRNA expression, with a Pearson correlation coefficient
of 0.73 (one-tailed p value 0.0015). However, when the
mRNA levels of MYCN in MNA cells were compared to
the corresponding protein levels (Fig. 2b, c), no linear
relationship could be found. The lack of correlation
between mRNA and protein levels points out to the pre-
sence of pronounced post-transcriptional (e.g., mRNA
stability, translation efficiency) and/or post-translational
(e.g., post-translational modifications leading to variation
in the protein degradation rate) mechanisms controlling
MYCN expression.
For initial testing we selected four MNA NB cell lines
(SiMa, CHP134, SK-N-BE(2), and KELLY) with different
DNA–RNA–protein ratios. To address the role of MYCN
30UTR in the modulation of mRNA fate, at first we pro-
duced two reporter constructs. Both constructs contained
the Firefly luciferase reporter gene under the control of the
CMV promoter followed by either the MYCN 30UTR
sequence (pGL4.26-MYCN) or the SV40 poly(A) region
(pGL4.26-CTRL) (Fig. S1). Then we tested how and to
which extent the presence of the MYCN 30UTR affected the
expression of the luciferase reporter. We transiently
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transfected the two plasmids in the four selected NB cell
lines. In all four cases, the introduction of MYCN 30UTR
resulted in a decrease of luciferase signal of about 70 %
(Fig. 3). The effect was not dependent on the CMV pro-
moter, since similar results were observed using the con-
structs with the SV40 promoter (data not shown). The
effect is also independent from the level of MYCN
amplification over a tenfold spectrum (compare Figs. 2a,
3). These data confirmed the existence in a NB cell envi-
ronment of general (not cell line specific) post-transcrip-
tional control mechanisms exerted through the MYCN
30UTR.
Development and Validation of the Assay
CHP134 was selected as a final cellular model for the assay
for several reasons. CHP134 has been reported to express
the antiapoptotic BCL2 gene at extremely low levels, and
to be used as a NB cell death model, i.e., cells would rather
undergo apoptosis than neuronal differentiation in response
to a treatment [23, 24]. In addition, the intermediate level
of MYCN mRNA expression in CHP134 cells compared to
SiMa cells from one side and SK-N-BE(2) and KELLY
cells from the other side, offered an opportunity of mod-
ulation of the mRNA in both directions: down-regulating
its expression and up-regulating it. Inhibition of MYCN
expression would be desirable because of the ‘‘oncogene
addiction’’ concept, i.e., cancer cells become dependent on
an activated oncogene, and therefore suppression of the
oncogene expression or activity could selectively impair
cancer cell survival [25]. Enhancement of MYCN expres-
sion might be also detrimental to cancer cells. During the
process of tumor development cells raise a barrier to the
intrinsic tumor suppression pathways; however, further up-
regulation of an activated oncogene capable of inducing
programmed cell death might overcome an upper threshold
of its tolerance by cancer cells causing death [26].
For the high-throughput format, the luciferase reporter
constructs pGL4.26-MYCN and -CTRL were stably inte-
grated in the CHP134 NB cell line. The clones were desig-
nated as CHP134-MYCN or CHP134-CTRL, respectively,
followed by the number corresponding to a specific clone.
To determine the feasibility of the assay, we verified if
luciferase activity could be up- and down-regulated specif-






























































































































































































Fig. 2 MYCN levels in parental NB cell lines. a Haploid MYCN
DNA copy number obtained by qPCR. The values are reported as
normalized to two reference genes (BCMA and SDC4) and calibrated
to a normal human gDNA sample. Mean ± SEM of at least three
biological replicates is shown. b Relative MYCN mRNA expression
levels normalized to geometric mean of four reference genes (HPRT1,
SDHA, GAPDH, UBC) as determined by qPCR. Mean ± SEM of at
least three biological replicates is reported. c The representative
western blot showing MYCN and GAPDH protein levels in 18 NB
cell lines

























Fig. 3 MYCN 30UTR down-regulates expression of a luciferase
reporter. The pGL4.26-MYCN and -CTRL plasmids were transiently
transfected in SiMa, CHP134, SK-N-BE(2), and KELLY cells as
described in ‘‘Materials and Methods’’ section. For each cell line,
normalized luciferase activity obtained in transfections with
pGL4.26-CTRL plasmid was set to 100 %. The luciferase signal
obtained in pGL4.26-MYCN transfections was expressed relative to
pGL4.26-CTRL. The mean ± SD of three biological replicates is
shown
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were transfected with miR-34a, shown to bind directly to the
MYCN 30UTR destabilizing it [17]. The implementation of a
modified reverse transfection protocol, i.e., cells were plated
immediately before the addition of transfection complexes
with miR-34a mimics, allowed us to measure the luciferase
activity within the time frame of the screening format.
Indeed, luciferase activity assessed 48 h after seeding/
transfection was 50 % less in miR-34a transfected cells
compared with that of the negative control (Fig. 4a), while
no evidence of cytotoxicity was detected under the tested
conditions (data not shown). This finding supported the
validity of MYCN 30UTR as a functional element able to
specifically down-regulate protein production, ectopically in
our system. Obtaining a positive control for up-regulation of
the reporter activity through MYCN 30UTR turned out to be
more complex. Transfection of miR-34a inhibitors into
CHP134-MYCN#3 cells did not change luciferase activity,
indicating that despite miR-34a is able to mediate its effects
when introduced into the cells artificially, it is not per se
functional in this cell line. As an alternative, the cells were
transfected with the plasmid overexpressing HuD, an RNA-
binding protein known to stabilize MYCN mRNA through
direct binding to its 30UTR [14]. Significant increase in
luminescence was detected after transfection of CHP134-
MYCN#3 cells with HuD (Fig. S2). However, this up-reg-
ulation could be detected only after 72 h after seeding/
transfection and not before, probably due to the time needed
for the synthesis of the HuD protein itself. Thus, although we
obtained the proof-of-principle increase mediated by HuD,
its overexpression could not be used as a screening control
due to the longer time between cell plating and assay end-
point. At the time when the described assay was under
development, there were no chemical components known to
act specifically through MYCN 30UTR. We therefore treated
CHP134-MYCN#3 cells with all-trans retinoic acid (ATRA)
that up-regulated the reporter activity twice (Fig. 4b) acting
most likely through the viral promoter and/or vector
sequences and not the 30UTR, since a similar increase was
detected in CHP134-CTRL#19 cells (data not shown).
Altogether, the functionality and specificity of the cell-based
assay was demonstrated using miR-34 mimics as negative
control and HuD as positive control. Including ATRA
treatment as positive control allowed us to calculate a Z-
factor of 0.75 and a signal to background ratio of 3.5 (Fig. 4)
indicating robust performance in the high-throughput
format.
Identification of Molecules Modulating MYCN
Expression Through Its 30UTR
A screening aimed at the identification of compounds able











































Fig. 4 Quality assessment of the assay. CHP134-MYCN#3 clonal
cells were plated in a white 96-well plate. a Immediately after plating
the cells were transfected with 25 nM miR-34a mimics and 25 nM
miScript negative control (NC) using modified reverse transfection
protocol. b The day after seeding the cells were treated with 2 lM all-
trans-retinoic acid (ATRA) or vehicle (NC). Luciferase activity was
assayed 48 h after seeding using One-Glo reagent (Promega). The
graph represents one of two biological replicates, the mean ± SD of
eight technical replicates is shown. Z-factor calculated from the data
is 0.75, suggesting that the assay will perform well in high-throughput
format























Fig. 5 Plate-well scatter plot of normalized values from the primary
screening. The screening of 2,000 compounds at 2 lM concentration
was carried out in CHP134-MYCN#3 cells. Each point corresponds to
luciferase activity detected for a single compound after 24 h of
treatment and normalized to the mean luciferase signal detected in
vehicle-treated controls within the same plate. Mean over three
replicates ± SD is shown
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out in the CHP134-MYCN#3 clone using a 2000 com-
pound library (Spectrum collection, Microsource Discov-
ery Systems, Inc.). The library included three main
categories of molecules: (i) about 50 % are drugs that have
been introduced in the US or are limited in use to Europe
and Japan; (ii) about 30 % are natural products; (iii) 20 %
are other compounds with known biological activities. The
luciferase activity was assessed after 24 h of a 2 lM
treatment. Examination of the data from different plates in
the screen, depicted in Fig. 5 as fraction of on-plate con-
trols, displayed an overall good screen performance. No
evidence of systematic errors manifested through unde-
sirable patterns could be observed. The higher rates of up-
regulating hits detected in the library plates n.15-n.21
compared with others apparently reflects a non-random
pattern of compounds distribution. In fact, these plates are
overpopulated with natural compounds sharing similar
molecular structure. Since the screening experiment was
carried out in triplicate, the coefficients of variation (CVs)
could be calculated for each compound providing an
additional measure of performance. The median and mean
CVs were 5.0 and 6.5, respectively, indicating a robust
assay (Fig. S3a). The day-to-day reproducibility between
the runs was also very high, as revealed by comparison
across three inter-run replicates of the plate n.25 (Fig.
S3b).
Putting the hit selection threshold above/below two
standard deviations from the mean value computed over all
assay values, approximately 130 compounds were priori-
tized. Then, the list was manually filtered favoring FDA-
approved drugs over other compounds for potential drug
repositioning, and discarding compounds with a general
mechanism of cytotoxicity (e.g., pesticides, DNA interca-
lators, protein synthesis inhibitors). Manual filtering of the
primary list prioritized 112 hits (Table S2) that were re-
tested and counter-screened for promoter effects (Fig. 6a)
and for the phenotypic outcome in terms of cell viability
(Fig. 6b).
Overall, the confirmatory screening in CHP134-
MYCN#3 cells reproduced very well the results of the
primary screening for the 112 selected compounds with a
Pearson correlation coefficient of 0.94 (p \ 0.0001) (Table
S2; Fig. S4). The viability WST-1 assay revealed that the
majority of the compounds inducing a decreased luciferase
activity also displayed cytotoxic effects (Fig. 6). The
counter-screening on CHP134-CTRL#19 clonal cells
enabled us to discriminate between the hits that caused
luciferase up-regulation through the MYCN 30UTR or
through the promoter of the reporter plasmid. The counter-
screening identified four drugs as truly dependent on
MYCN 30UTR, three of which belonged to the anthracy-
clines class (daunorubicin (N5), doxorubicin (N33), epi-
rubicin (N35)), while the fourth was ciclopirox olamine
(CPX) (N3), a synthetic antifungal compound belonging to
the hydroxypyridones class.
Validation of the CPX Hit
CPX was selected for the final step quality assessment of
the assay since it did not compromise the cell viability at
the concentration used in the screening and thus did not
require any additional experiments for concentration
adjustments. To prove dose-dependence of CPX effect for
MYCN 30UTR and its clone-independency, the treatment
was extended to two concentrations, 2 and 5 lM, in four
clones, i.e., CHP134-MYCN#3 and CHP134-CTRL#19
used in the counter-screening and the independent clones
CHP134-MYCN#1 and CHP134-CTRL#17. Measurement
of luciferase activity with the One-Glo luciferase assay
after 24 h proved the clone-independency of the results
obtained before (Fig. 7). Moreover, the effect of increased
luciferase expression became even more evident upon
treatment with 5 lM CPX.
Though the values of the WST-1 assay demonstrated
about twofold increase in cell viability (Fig. 6b), no obvi-
ous difference in cell number could be observed under
microscope as compared to vehicle-treated controls. This
discrepancy was addressed by counting viable cells in all
clones, either vehicle-treated or treated with 2 and 5 lM
CPX. As shown in Fig. 7, 2 lM CPX had very little effect
on CHP134 cell viability in 24 h, whereas treatment of
cells with 5 lM CPX decreased number of viable cells to
about one-half of the control. Taken together, it is possible
to conclude that CPX elicited a clone-independent, MYCN
30UTR specific effect on increased luciferase expression in
CHP134 NB cells.
Finally, we investigated whether the effect of CPX on
the MYCN 30UTR detected by reporter cell-based assay
could be recapitulated under physiological conditions, i.e.,
if CPX treatment was able to modulate MYCN protein
levels. Given the high abundance of MYCN protein in
CHP134 cells (Fig. 2), this substantial background might
render visualization of slight differences in total protein
levels very difficult. Therefore, taken into account that
MYCN protein has mostly nuclear localization, the dif-
ferences in de novo synthesized protein could be appreci-
ated better by separation of the cytoplasmic fraction from
the rest.
Following the outline of the screening, the parental
CHP134 cells were treated with 2 lM CPX for 24 h fol-
lowed by western blot analysis. Surprisingly, the treatment
resulted in down-regulation of MYCN protein expression
and not in its up-regulation as predicted by the screening
results. Taking into account the half-life time of MYCN
protein of about 30 min, earlier time points were verified.
In fact, an increase in MYCN protein could be detected as
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short as 1 h after initiation of the treatment with a peak
around 2 h and a final decrease by 24 h (Fig. 8). The
apparent inconsistency in timing of CPX effects revealed
by western blot analysis and by the reporter assay was
clarified after evaluation of the stability of the luciferase
protein. Firefly luciferase in CHP134 cells turned out to
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Fig. 6 Counter-screening of 112 compounds. a Luciferase assay was
performed in CHP134-MYCN#3 and -CTRL#19 cells and b WST-1
assay in CHP134-MYCN#3 for 112 pre-selected hits, each at 2 lM
for 24 h. a Each bar corresponds to luciferase activity detected for a
single compound and normalized to the mean luciferase signal
detected in DMSO-treated controls within the same plate. b Cell
viability was calculated as described in ‘‘Materials and Methods’’
section. Mean over three replicates ± SD is reported
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have a half-life time of more than 9 h (data not shown),
allowing for the detection of the early events even after
24 h.
To rule out the possibility that up-regulation of the
MYCN protein is a consequence of transcriptional changes,
we performed qPCR analysis. In agreement with the data of
the screening indicating a post-transcriptional mode of
CPX effects on MYCN, qPCR analysis revealed the lack of
a concomitant increase in MYCN mRNA levels within the
first hours of CPX treatment. This result indicated that CPX
treatment did not affect the stability of the MYCN tran-
script either, thus excluding this mechanism of post-tran-
scriptional regulation as the cause of the MYCN protein
increase.
To sum up, the developed cell-based reporter gene assay
allowed us to identify molecules modulating protein levels
via post-transcriptional mechanisms dependent on a
30UTR. Moreover, we successfully extrapolated CPX-
mediated MYCN 30UTR-dependent up-regulation of lucif-
erase on endogenous MYCN protein expression. The
increased MYCN expression upon CPX treatment could
most likely result from enhanced translational efficiency of
its mRNA, due to changed polysomal loading and/or
ribosomal occupancy of the MYCN transcript. Further
studies are required to unveil the exact molecular mecha-
nism underlying the reported effect.
Discussion
MYCN is together with MYC and MYCL a member of the
MYC family of transcription factors that have roles in
many if not all aspects of cell fate including cell prolifer-
ation and growth, survival and differentiation [27]. It is
therefore not surprising that deregulation of MYC proteins
contributes to the development of a wide variety of human
cancers. In particular, the amplification of MYCN gene is
the most common focal genetic lesion in sporadic NB. It
occurs in about 22 % of NB tumors and is associated with
advanced stages of disease, rapid tumor progression and
poor prognosis [13]. MYCN amplification and consequent
overexpression has been also found in other cancers of
neural origin, including glioblastoma, medulloblastoma,
retinoblastoma, small cell lung carcinoma, peripheral
neuroectodermal tumors [28].
Despite deregulation of MYCN is a marker of high-risk
NB, there are currently no clinical trials aiming the MYCN
protein directly [11]. Transcription factors including
MYCN itself have traditionally been considered as very
difficult for pharmacological targeting, since their function
is largely mediated through protein–protein interactions
rather than enzymatic activities, and it is difficult to design
specific small molecules to interrupt these large surface
































Fig. 7 Clone-independency of the CPX effect on MYCN 30UTR.
One-Glo luciferase assay was performed in CHP134-MYCN#3,
-MYCN#1, -CTRL#19 and -CTRL#17 cells grown in 96-well plates
and treated for 24 h with 2 (dark gray bar) and 5 lM (light gray bar)
CPX. Amount of viable cells (Hoechst?, PI-) upon treatment with
2 lM (black circles) and 5 lM (black triangles) CPX was counted
using high-content imaging system Operetta (PerkinElmer). Data are
expressed relative to vehicle-treated controls. Mean ± SEM of three
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Fig. 8 The effects of CPX treatment on MYCN levels. CHP134 cells
treated with 2 lM CPX were harvested at specified time points. For
each condition RNA and protein lysates were prepared. 20 lg of cell
cytoplasmic or 10 lg of total protein lysates was loaded and
electrophoresed using SDS-PAGE and transferred to nitrocellulose
membrane. Proteins were detected using anti-MYCN and anti-
GAPDH. a The representative western blots of three biological
replicates are displayed. b The bar graph shows quantification of
MYCN protein after normalization using the levels of GAPDH
protein; cytoplasmic MYCN levels are represented by dark gray bars,
total MYCN by light gray bars. White bars correspond to relative
MYCN mRNA expression levels normalized to geometric mean of
HPRT1 and SDHA reference genes as determined by qPCR.
Mean ± SEM of three biological replicates is reported
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interactions. Alternative pharmacological approaches to
deal with the deregulated MYCN expression are focused
on its mRNA, with the aim of either suppressing its pro-
duction or favoring its degradation. The best-known
example of a compound able to decrease MYCN mRNA
production is retinoic acid (RA) [29]. Transcriptionally
mediated down-regulation of MYCN is a pivotal event in
RA-induced differentiation of NB cells. Indeed, the use of
RA is currently part of a protocol used for the treatment of
high-risk NB [30]. As to the second strategy, selective
knocking down of a gene’s expression through sequence-
specific binding of RNA molecules is of particular interest
in drug discovery and development. Knockdown of MYCN
expression with antisense oligonucleotides in MNA NB
has been reported to decrease tumorigenesis in mouse
model underlying the potential of this strategy for NB
therapy [31].
In this report we focus on yet another approach to
address deregulated MYCN expression, namely to target its
mRNA fate via modulation of post-transcriptional control
mechanisms. The fact that examination of 14 MNA NB
cell lines for MYCN status revealed a lack of correlation
between mRNA and protein levels supports the functional
importance of these control mechanisms for MYCN
deregulated expression (Fig. 2). Post-transcriptional regu-
lation of MYCN expression is largely exerted through the
MYCN 30UTR as can be predicted by the high level of its
conservation in vertebrate phylogenesis. In particular, the
MYCN 30UTR influences the gene expression via modula-
tion of its mRNA decay. This effect is largely mediated by
cis-acting destabilizing elements residing within the 30UTR
sequence [14]. In addition, several miRNAs affect MYCN
protein levels via interaction with its 30UTR, resulting in
translational repression [16–19, 32]. Also in the NB cells
tested, the MYCN 30UTR was shown to affect mRNA fate,
since its introduction to the reporter plasmid reduced
luciferase activity to 30–40 % of the control value (Fig. 3).
Moreover, in CHP134 cells both mRNAs, the endogenous
MYCN and the luciferase reporter followed by MYCN
30UTR, showed a similar half-life time of about 30 min
(data not shown) further supporting the functionality of the
30UTR sequence.
To identify compounds able to modulate MYCN mRNA
fate via mechanisms dependent on its 30UTR, the stable
cell line CHP134-MYCN was generated and characterized
as a sensitive and reliable luciferase reporter assay. Using
this approach changes in luciferase activity serve as indi-
rect measure of affected mRNA stability and/or translation
efficiency. MYCN 30UTR conferred responsiveness to the
luciferase reporter following transient transfection of miR-
34a mimic and HuD overexpressing plasmid, thus vali-
dating the model. Application of this cellular model for
testing 2000 compounds produced over 100 potential hits,
both inhibitors and stimulators of luciferase activity. The
counter-screening of 112 selected compounds allowed to
subdivide all of them in two groups according to viability
data. Compounds of the first group caused an efficient
cytotoxicity in CHP134 cells, while the other group had no
significant impact on viability under the settings used in the
screening. Comparison between luciferase activity and the
corresponding cell viability data displayed very strong
correlation between the two (Pearson coefficient of 0.907
with p value \ 0.0001). In other words, significant
decrease of luciferase activity was largely a consequence of
cytotoxic effects. In this context, specific effects of MYCN
30UTR could be overlooked for the compounds with pro-
nounced cytotoxicity resulting in false negative hits. That
could account for a failure to detect down-regulating hits
truly dependent on the MYCN 30UTR. Further titration
would be necessary for the compounds that at 2 lM con-
centration caused significant reduction in viability. This
would allow us to select an appropriately lower concen-
tration in order to discriminate if a compound of interest
exert a specific effect on the MYCN 30UTR.
Recently Frenzel et al. [33] screened 80 conventional
cytotoxic drugs in order to identify the compounds whose
effect on cell viability could be potentiated by MYCN
overexpression. From 19 drugs shown to be more effective
in the MYCN overexpressing cells, 13 were present in the
Spectrum Collection library and 12 were selected in our
primary screening for the counter-screening. The 13th drug
cycloheximide, in fact, also passed the threshold for hit
selection, but was not followed in the counter-screening
based on our previous knowledge about its effective con-
centration in CHP134 cell model. This striking overlap
highlights a validity of the chosen cellular model.
Another valuable information was retrieved by cluster-
ing the hits based on chemical and functional similarity.
The largest inhibitor group was composed by chemother-
apeutic drugs including three of six drugs commonly used
for treatment of NB (vincristine, etoposide and doxorubi-
cin). Of note, verification why the remaining three drugs
(topotecan, cyclophosphamide and cisplatin) were not
counter-screened revealed that one of them, topotecan, is
not present in the Spectrum collection library. Cyclo-
phosphamide is a prodrug, i.e., it should be converted to its
active form through the normal metabolic processes of the
body. Finally, cisplatin was the only of the six compounds
to which CHP134 cells were quite resistant, demonstrating
IC50 values in the micromolar range (data not shown).
The whole class of cardiac glycosides included in the
Spectrum Collection library (13 compounds) was repre-
sented in the hit list. Cardiac glycosides are a family of
naturally derived compounds that bind to and inhibit the
sodium pump. The increased susceptibility of cancer cells
to these compounds supports their potential use as
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antitumor agents, and the first generation of glycoside-
based anticancer drugs have now entered clinical trials for
treating cancer [34]. There is some preclinical evidence for
the anticancer properties of cardiac glycosides in NB.
Kulikov et al. [35] demonstrated in vitro that ouabain
triggers a variety of signaling pathways ultimately leading
to NB cell death. Svensson et al. [36] showed that digoxin
causes a specific NB growth inhibition in mice grafted with
two NB cell lines, SH-SY5Y and Neuro-2a.
Finally, most of the hits endowed with up-regulating
luciferase activity belonged to a big group of natural
compounds called flavonoids. However, detection of
increased luciferase activity upon treatment with flavo-
noids in both CHP134-MYCN and -CTRL cells indicated
that this increase was not due to the presence of the 30UTR
sequence. The most prominent up-regulation of luciferase
activity was detected upon treatment with tretinoin
(ATRA) and isotretinoin (13-cis RA). RA exerts its activity
by binding distinct members of the retinoid superfamily of
nuclear receptors, which have been reported to affect
luciferase expression from viral promoters [37]. This effect
was dependent on both viral promoter and luciferase
reporter itself. Also other flavonoids, given their high
degree of structural similarity with RA, are very likely to
mediate their effects through the CMV viral promoter and/
or some sequences within the luc2 gene. Up-regulation of
the luciferase signal by flavonoids turned out to be not
specific, resulting in a high rate of false positive hits.
Treating the cells with a transcription inhibitor before drug
addition would help to discriminate if the changes in
luciferase signal are due only to the effects mediated
through the 30UTR or are the consequence of transcrip-
tional events. While this option is to be considered for
shorter treatments (hours), caution should be taken for
screenings with prolonged incubation times (24 h or more)
since transcriptional blocking itself would have deleterious
effects on cells.
Despite the fact that the rationale of the screening was to
identify compounds able to down-regulate MYCN
expression so reducing the oncogenic potential of MYCN,
4 compounds selected in the screening were able to up-
regulate MYCN, but inducing efficient cytotoxicity as well
(Fig. 6). A possible reason of this paradoxical outcome
could rely on two opposite functions exhibited by the MYC
family proteins. MYC proteins promote cell growth and
proliferation, however their activation provokes intrinsic
safeguard mechanisms including apoptosis, cellular
senescence and DNA damage response [27]. During the
process of tumor development, proliferation needs to be
uncoupled from apoptosis [26]. This barrier is overcome
under the form of a variety of mutations, which inactivate
coordinated networks responsible for cell death thus
shifting the equilibrium toward anti-apoptotic determi-
nants. The compensating mutations accumulated during
tumorigenesis will determine an upper threshold of toler-
ance for the oncogene. Therefore, additional over-activa-
tion of the already activated oncogene such as MYCN
could determine a massive overcoming of the barriers
resulting in extinction of the cells bearing the activated
oncogene.
Among the 4 molecules selected as truly dependent on
MYCN 30UTR, 3 are well-known chemotherapeutic agents
belonging to the anthracycline class, which is used in the
first line treatment of NBs (doxorubicin, daunorubicin and
epirubicin). The fourth molecule is a topically used an-
tifungine compound, CPX. CPX as well as a big pro-
portion of other compounds in the Spectrum Collection
library are FDA-approved drugs with already well-estab-
lished pharmacodynamics and pharmacokinetics. Finding
new applications for these compounds would provide a
shorter pathway to clinical trials for treatment of other
diseases. This drug repositioning strategy is increasingly
used since it not only decreases times to the clinic but
also significantly reduces the costs and improves success
rates. Though originally developed as antimicotic agent,
CPX has recently been demonstrated to be an effective
anti-tumor agent for the treatment of leukemia and mye-
loma cells in vitro [38]. An ongoing study is evaluating
anti-cancer properties of CPX in patients with relapsed or
refractory hematologic malignancy (http://www.clin
icaltrials.gov). To our knowledge, CPX has not been
investigated in relation to NB yet. It would be of interest
to investigate the potential of CPX as NB therapeutic
agent.
In conclusion, we described a biological model that
enables the identification of compounds modulating the
level of a protein of interest by specifically targeting post-
transcriptional control mechanisms. Post-transcriptional
regulation represents a mechanism of biomedical interest
with a potential for pharmacological intervention. This
approach offers several advantages. First, it creates novel
biological targets for drug design potentially resulting in
ability to treat diseases with no cure at the moment. Sec-
ond, it allows to screen for mechanisms not only inhibiting
the protein production but also increasing the levels of the
targeted proteins. Third, perturbing post-transcriptional
gene expression controls offers an alternative approach for
difficult-to-target proteins.
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